Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 15/20 | 0.45 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31003191 | 0.79 | ACACB (0.50) | ACACBFFAR1HRH3 | |
| SCHEMBL25189393 | 0.78 | AOC3 (0.59) | — | |
| SCHEMBL25179834 | 0.77 | ACACB (0.40) | ACACBGRIN1GRIN2BFFAR1 | |
| SCHEMBL18070205 | 0.76 | HRH3 (0.49) | GRIN1GRIN2BHRH3 | |
| SCHEMBL13720815 | 0.75 | ACACB (0.49) | ACACBFFAR1HRH3 | |
| SCHEMBL20738579 | 0.75 | ABCB11 (0.47) | ACACBFFAR1HRH3 | |
| SCHEMBL18101741 | 0.74 | ACACB (0.44) | ACACBFFAR1HRH3 | |
| SCHEMBL18101746 | 0.74 | ACACB (0.44) | ACACBFFAR1HRH3 | |
| SCHEMBL11534496 | 0.73 | SRD5A2 (0.46) | ACACB | |
| SCHEMBL4919262 | 0.73 | HRH3 (0.67) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250326746-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. | 2025-10-23 | — | — | US | disclosed |
| US-12234231-B2 | EIF4E inhibitors and uses thereof | PIC Therapeutics, Inc. (US) | 2025-02-25 | — | — | US | disclosed |
| EP-4392422-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. (US) | 2024-07-03 | — | — | EP | disclosed |
| CN-118103368-A | EIF4E inhibitors and uses thereof | 皮克医疗公司 | 2024-05-28 | — | — | CN | disclosed |
| US-20230150997-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. | 2023-05-18 | — | — | US | disclosed |
| US-20230150997-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. | 2023-05-18 | — | — | US | disclosed |
| US-20230150997-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. | 2023-05-18 | — | — | US | disclosed |
| WO-2023028235-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. (US) | 2023-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250326746-A1 | EIF4E INHIBITORS AND USES THEREOF | EIF4E, EIF4EBP1, EIF4A1 | ACACB 3319/4885GRIN1 3262/4885GRIN2B 3212/4885 |
| US-20230150997-A1 | EIF4E INHIBITORS AND USES THEREOF | EIF4E, EIF4EBP1, EIF4A1 | ACACB 3319/4885GRIN1 3262/4885GRIN2B 3212/4885 |
| US-12234231-B2 | EIF4E inhibitors and uses thereof | EIF4E, EIF4EBP1, EIF4A1 | ACACB 3319/4885GRIN1 3262/4885GRIN2B 3212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.